Chlorthalidone vs. Hydrochlorothiazide for Treatment of Hypertension

KARYN SPRINGER, MD, Utah Valley Family Medicine Residency, Provo, Utah

Clinical Question
Is chlorthalidone more effective than hydrochlorothiazide for treatment of hypertension?

Evidence-Based Answer
Chlorthalidone produces slightly greater reductions in blood pressure compared with hydrochlorothiazide (HCTZ), but it is associated with greater declines in serum potassium levels. (Strength of Recommendation [SOR]: C, based on a meta-analysis of disease-oriented evidence.) Chlorthalidone lowers the risk of cardiovascular events about 18% more than HCTZ at the same achieved blood pressure. (SOR: B, based on a meta-analysis.)

In 2010, a meta-analysis of 137 randomized controlled trials (RCTs; N = 5,843) examined the effectiveness of chlorthalidone and HCTZ as monotherapy for hypertension. A total of 29 trials of chlorthalidone (N = 2,995; dose range = 12.5 to 200 mg, median 25 mg) and 108 trials of HCTZ (N = 2,848; dose range = 3 to 450 mg, median 33 mg) were analyzed based on dose and study duration (all less than one year). When all study durations were pooled, 12.5 to 25 mg of chlorthalidone produced a statistically greater reduction in systolic blood pressure compared with HCTZ (–24 mm Hg vs. –14 mm Hg; P < .05). In studies of 12 to 52 weeks’ duration, the use of chlorthalidone resulted in statistically greater reductions in serum potassium levels (–0.40 mEq per L [–0.40 mmol per L] vs. –0.24 mEq per L [–0.24 mmol per L]; P = .008). HCTZ and chlorthalidone were not directly compared in these RCTs.

A meta-analysis of nine RCTs (N = 78,350) examined the reduction in cardiovascular events in patients receiving chlorthalidone (six trials, N = 59,976; dose range = 12.5 to 100 mg) and HCTZ (three trials, N = 18,374; dose range = 12.5 to 50 mg). Cardiovascular events were defined as myocardial infarction or new diagnosis of coronary heart disease, stroke, or congestive heart failure. When comparing patients with the same mean decrease in systolic blood pressure, the risk of cardiovascular events was lower in patients receiving chlorthalidone compared with those receiving HCTZ (risk ratio [RR] = 0.82; 95% confidence interval, 0.70 to 0.97). However, there were no head-to-head comparisons of chlorthalidone and HCTZ in these trials.

A 2006 randomized, single-blind crossover study (eight-week treatment plus a four-week washout) compared the effects of chlorthalidone (12.5 mg titrated to 25 mg) and HCTZ (25 mg titrated to 50 mg) on 24-hour ambulatory blood pressure. The study included 30 patients who had stage 1 or 2 hypertension and were not currently taking antihypertensive medications. This trial was not included in the meta-analyses discussed previously because of its crossover design. At week 8, there was no statistical difference in reduction of 24-hour mean ambulatory systolic blood pressure between patients receiving 25 mg of chlorthalidone and those receiving 50 mg of HCTZ (–12 mm Hg vs. –11 mm Hg; P = .54). At week 2, office systolic blood pressure reduction was greater in patients receiving chlorthalidone (–16 mm Hg vs. –4.5 mm Hg; P = .001), but by week 8 the reductions were not statistically significant (–17 mm Hg vs. –11 mm Hg; P = .84). Only data from the first active treatment period were analyzed because there was a significant “order-drug-time” interaction in which patients receiving chlorthalidone had
significantly greater blood pressure reduction when the medication was given before the HCTZ arm. This trial was limited by its short duration.

The Eighth Joint National Committee recommends thiazide diuretics as one option for initial therapy for hypertension because of their effects on overall mortality and cardiovascular outcomes. Further head-to-head comparisons between chlorthalidone and HCTZ would be useful to determine if either medication is superior in terms of cardiovascular benefits.

Copyright Family Physicians Inquiries Network. Used with permission.

Address correspondence to Karyn Springer, MD, at karyn.springer@imail.org. Reprints are not available from the author.

Author disclosure: No relevant financial affiliations.

REFERENCES

GET IN THE GAME
with FREE resources for you and your patients on the importance of concussion safety from the AAFP and NFL Foundation.
aafp.org/concussion-awareness

FOR YOU
Concussion Webcasts
Watch a series of three webcasts designed to provide you with sport concussion basics and knowledge on individual care-based management.

FOR YOUR PATIENTS
Educational Brochure
Help your patients understand what a concussion is, learn about the long-term brain health in athletes, as well as the limitations of protective equipment.

Funding and support for this material have been provided by the National Football League Foundation.